PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 123 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $115,000 | 0.0% | 14,252 | -7.9% | 0.00% | 0.0% |
| Q1 2018 | $115,000 | -19.0% | 15,467 | -35.2% | 0.00% | 0.0% |
| Q4 2017 | $142,000 | +246.3% | 23,861 | +145.3% | 0.00% | – |
| Q2 2016 | $41,000 | +7.9% | 9,729 | +12.4% | 0.00% | – |
| Q1 2016 | $38,000 | -5.0% | 8,652 | +32.6% | 0.00% | – |
| Q4 2015 | $40,000 | -18.4% | 6,527 | -23.8% | 0.00% | – |
| Q3 2015 | $49,000 | +145.0% | 8,564 | +216.6% | 0.00% | – |
| Q2 2015 | $20,000 | – | 2,705 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |